Merck Vaccine Shows 49% Melanoma Benefit at 5 Years, Gardasil Sales Slump
Merck and Moderna’s mRNA-4157/V940 combined with Pembrolizumab reduced recurrence or death risk by 49% at five years in high-risk melanoma patients in a Phase 2b study. Sharp Gardasil sales declines in China and Japan are expected to pressure Merck’s Q4 revenues.
Related News
NVDA
Nvidia Posts 85% Revenue Surge to $81.6B, Forecasts $91B Next Quarter
NVDA•
AMZN
AWS Faces Challenge as Nvidia Forecasts $91B Q3 Sales, Musk Eyes 2028 Space Data Centers
AMZN•
DE
Menon Bearings Posts 23% Revenue Gain, 51 New Parts for Deere Supply
DE•
AAPL
Apple App Store Blocks 1 Billion Fake Accounts, Prevents $2.2B Fraud
AAPL•
TJX
TJX Beats Q1 EPS by $0.20, Comps Up 6% and Spain Store Launch
TJX•
Sources
ZBB